Assembly Biosciences’ (ASMB) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Assembly Biosciences (NASDAQ:ASMB) in a research report sent to investors on Friday,Benzinga reports.

Separately, Jefferies Financial Group upgraded shares of Assembly Biosciences from a “hold” rating to a “buy” rating and upped their target price for the company from $2.00 to $35.00 in a report on Friday, September 20th.

Assembly Biosciences Price Performance

NASDAQ ASMB opened at $15.16 on Friday. Assembly Biosciences has a fifty-two week low of $9.12 and a fifty-two week high of $19.93. The business has a fifty day moving average of $16.05 and a 200-day moving average of $15.59.

Insider Buying and Selling at Assembly Biosciences

In other Assembly Biosciences news, major shareholder Alexander Schornstein purchased 10,000 shares of the stock in a transaction on Tuesday, October 8th. The stock was bought at an average price of $14.58 per share, for a total transaction of $145,800.00. Following the acquisition, the insider now directly owns 703,113 shares of the company’s stock, valued at $10,251,387.54. This represents a 1.44 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders sold 394 shares of company stock worth $5,894. Insiders own 5.10% of the company’s stock.

Institutional Investors Weigh In On Assembly Biosciences

Several hedge funds have recently modified their holdings of ASMB. JPMorgan Chase & Co. increased its position in Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock worth $53,000 after purchasing an additional 3,442 shares during the last quarter. FMR LLC increased its holdings in shares of Assembly Biosciences by 29.7% during the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock worth $240,000 after buying an additional 3,635 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Assembly Biosciences by 131.0% in the 2nd quarter. Acadian Asset Management LLC now owns 13,558 shares of the biopharmaceutical company’s stock worth $184,000 after buying an additional 7,690 shares during the period. Renaissance Technologies LLC boosted its holdings in Assembly Biosciences by 39.2% in the second quarter. Renaissance Technologies LLC now owns 54,911 shares of the biopharmaceutical company’s stock valued at $753,000 after acquiring an additional 15,451 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in Assembly Biosciences during the second quarter valued at about $6,421,000. 19.92% of the stock is owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.